MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1

Decera Clinical Education Oncology Podcast · Aug 28, 2020 · 26m

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET exon 14 testing and selecting MET-targeted therapies for patients with advanced NSCLC with topics including:

Incorporating MET exon 14 testing into standard of care

Comparison of RNA-based and DNA-based NGS platforms

Availability of RNA-based NGS testing around the world

Using FISH to quantify MET copy gain/amplification

Regulatory and clinical differences between new, selective MET inhibitors

Safety profiles of type I vs type II MET inhibitors

Counseling patients on…